Skip to main content

Table 1 Clinical characteristics of participants during the study period

From: Plasma proteome and metabolome characterization of an experimental human thyrotoxicosis model

Characteristics baseline 4 weeks (L-T4)a 8 weeks (L-T4)a 12 weeks 16 weeks β (SD)b Logc P value(SD)d
Age, years 27.8 (3.8) 27.8 (3.8) 27.8 (3.8) 27.8 (3.8) 27.8 (3.8)
BMI, kg/m2 24.1 (2.4) 24.1 (2.4) 24.1 (2.4) 24.1 (2.4) 24.1 (2.4)
FT4, pmol/L 13.2 (1.4) 28.6 (6.5) 25.9 (5.7) 11.5 (1.5) 12.8 (1.5) <0.001e
FT3, pmol/L 5.27 (0.51) 9.19 (2.01) 8.92 (2.25) 4.61 (0.33) 4.86 (0.55) 2.76 × 10–1 (8.22 × 10–3) no 7.43 × 10–25 (4.28 × 10–24)f
TSH, mU/L 2.104 (1.017) 0.017 (0.029) 0.007 (0.007) 2.298 (1.309) 2.177 (0.897) –1.35 × 10–1 (6.42 × 10–3) yes 7.26 × 10–21 (2.02 × 10–20)f
SHBG, nmol/L 30.2 (10.2) 50.6 (16.2) 55.9 (16.3) 36.3 (11.8) 29.3 (9.3) 1.41 × 10–2 (9.11 × 10–4) yes 3.41 × 10–10 (1.03 × 10–9)f
Cystatin C, mg/L 0.68 (0.06) 0.79 (0.08) 0.86 (0.12) 0.71 (0.07) 0.68 (0.06) 4.19 × 10–3 (2.35 × 10–4) yes 8.26 × 10–9 (1.10 × 10–8)f
Serum glucose, mmol/L 5.18 (0.35) 5.22 (0.42) 5.26 (0.39) 5.09 (0.31) 5.18 (0.57) 5.76 × 10–3 (1.62 × 10–3) no 2.91 × 10–1 (1.38 × 10–1)
Insulin, μU/L 8.35 (3.63) 7.94 (4.32) 7.78 (3.62) 8.33 (4.06) 8.07 (3.38) –1.29 × 10–3 (1.14 × 10–3) yes 6.58 × 10–1 (2.29 × 10–1)
HDL-cholesterol, mmol/L 1.43 (0.27) 1.21 (0.20) 1.23 (0.25) 1.46 (0.29) 1.42 (0.37) –1.30 × 10–2 (8.89 × 10–4) no 1.33 × 10–5 (1.54 × 10–5)f
LDL-cholesterol, mmol/L 2.70 (0.72) 2.15 (0.57) 2.27 (0.53) 2.91 (0.75) 2.76 (0.79) –4.18 × 10–2 (1.96 × 10–3) no 2.91 × 10–8 (6.08 × 10–8)f
Cholesterol, mmol/L 4.53 (0.75) 3.81 (0.61) 4.06 (0.61) 5.04 (0.70) 4.61 (0.68) –5.87 × 10–2 (2.24 × 10–3) no 3.05 × 10–10 (6.84 × 10–10)f
Triglycerides, mmol/L 1.26 (0.76) 1.14 (0.58) 1.29 (0.56) 1.31 (0.63) 1.35 (0.82) –1.96 × 10–3 (6.06 × 10–4) yes 3.08 × 10–1 (1.65 × 10–1)
ALT, μkatal/L 0.51 (0.21) 0.38 (0.10) 0.65 (0.42) 0.61 (0.29) 0.50 (0.14) –4.30 × 10–3 (9.65 × 10–4) yes 9.99 × 10–2 (7.00 × 10–2)
AST, μkatal/L 0.49 (0.41) 0.34 (0.14) 0.43 (0.17) 0.43 (0.14) 0.43 (0.23) –2.03 × 10–3 (1.30 × 10–3) yes 4.67 × 10–1 (2.37 × 10–1)
GGT, μkatal/L 0.41 (0.09) 0.45 (0.11) 0.49 (0.11) 0.45 (0.15) 0.43 (0.11) 6.84 × 10–4 (8.20 × 10–4) yes 6.55 × 10–1 (3.18 × 10–1)
Total bilirubin, μmol/L 12.5 (8.4) 12.6 (8.7) 13.5 (7.3) 11.9 (6.4) 11.9 (7.3) 1.56 × 10–3 (1.18 × 10–3) yes 5.83 × 10–1 (2.35 × 10–1)
Direct bilirubin, μmol/L 2.86 (1.35) 3.04 (1.35) 3.28 (1.24) 2.84 (1.03) 3.03 (1.39) 3.00 × 10–3 (5.14 × 10–4) yes 1.06 × 10–1 (6.69 × 10–2)
Complement C3, g/L 1.15 (0.27) 1.21 (0.16) 1.17 (0.11) 1.10 (0.14) 1.11 (0.14) 4.49 × 10–3 (5.06 × 10–4) no 2.38 × 10–2 (1.75 × 10–2)f
Complement C4, g/L 0.24 (0.06) 0.25 (0.05) 0.24 (0.05) 0.23 (0.05) 0.24 (0.05) 9.81 × 10–4 (1.38 × 10–4) no 3.09 × 10–2 (2.94 × 10–2)f
  1. a L-T4 application of levothyroxine
  2. bMean and standard deviation (SD) of the estimate for FT4 in linear mixed regression models adjusted for age and body mass index (BMI) from 101 subsamples
  3. cDependent variable was logarithmized to base 10
  4. dMean and SD of the P value
  5. eRepeated measurement analysis of variance adjusted for age and BMI
  6. fSignificant results
  7. FT 4 free thyroxine, FT 3 free triiodothyronine, TSH thyrotropin, SHBG sex hormone binding globulin, HDL high-density lipoprotein, LDL low-density lipoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transpeptidase